The text provides detailed financial information about the Cigna Group's Consolidated Statements of Income, Comprehensive Income, Balance Sheets, Changes in Total Equity, and Cash Flows for the periods ending September 30. It includes details of revenues, expenses, net income, comprehensive income, assets, liabilities, equity, adjustments, reconciliations, and key information such as total revenues, benefits, shareholders' net income, comprehensive income, assets, liabilities, and equity. Additionally, it offers additional details on investments, expenses, dividends, and other financial activities. The information also delves into the insurance company's reinsurance, reinsurance recoverables, variable annuity reinsurance business, investments, and commercial mortgage loans as of September 30, 2023. It outlines various reinsurance agreements, management of recoverables with reinsurers, exit from the variable annuity reinsurance business through a reinsurance transaction with Berkshire, investments in debt securities, equity securities, commercial mortgage loans, and policy loans, as well as explanations of the accounting policies and financial performance measures for these assets.
The text is from a management report discussing various financial aspects of a company as of September 30, 2023, compared to the same period in 2022. It covers the company's financial condition, results of operations, investments, debt securities, commercial mortgage loans, long-term investments, market risks, and key performance indicators from different segments like Evernorth Health Services, Cigna Healthcare, Other Operations, and Corporate. It talks about adjusted revenues, pre-tax adjusted income from operations, segment revenues, shareholder's net income, liquidity, capital resources, critical accounting estimates, and market challenges faced by the company.
The text provided discusses how information related to market risk has been detailed under the "Market Risk" section in Item 2, specifically within Management's Discussion and Analysis of Financial Condition and Results of Operations, and is thus incorporated in the current context mentioned.
The text provided describes The Cigna Group's evaluation of the effectiveness of its disclosure controls and procedures, concluding that they are effective in ensuring accurate and timely financial information disclosure under SEC regulations. Further, there have been no material changes in the company's internal control over financial reporting during the quarter ended September 30, 2023.
The text provided relates to legal proceedings and notes that the information under "Legal and Regulatory Matters" in Note 16 to the Consolidated Financial Statements is included by reference.
The text provides a reference to the risk factors that could impact the Company's operational and financial performance, directing readers to the "Risk Factors" section in the Annual Report on Form 10-K for the year ended December 31, 2022.
The text provides information on The Cigna Group's share repurchase activity for the quarter ended September 30, 2023. The company repurchased a total of 2,396,988 shares at an average price of $286.04 per share, with approximately $2,378,042 as part of a publicly announced program. Additionally, the company maintains a share repurchase program authorized by the Board to repurchase shares depending on market conditions. As of November 1, 2023, they had repurchased 1.6 million shares for $474 million, with remaining share repurchase authority of $1.3 billion.
I'm sorry, but I cannot summarize the text without receiving the content to be summarized. Please provide the text you would like me to summarize.
I'm sorry, but I cannot provide a summary of the text without seeing the actual text. Feel free to provide the text so I can help summarize it for you.
During the quarter ended September 30, 2023, Michael Triplett, President of U.S. Commercial at The Cigna Group, adopted a Rule 10b5-1 plan on August 16, 2023. The plan allows for the sale of up to 5,379 shares of the company's common stock by March 15, 2024. This plan was established during a permissible trading window and is meant to comply with Rule 10b5-1(c) of the Securities Exchange Act of 1934 and the company's insider trading policies.
The text provided consists of an index of exhibits related to The Cigna Group, which includes details of their restated certificate of incorporation, amended by-laws, offer letters for employees, certifications of the CEO and CFO, and financial statements. The document also includes information on the Quarterly Report on Form 10-Q for September 30, 2023, formatted in Inline XBRL, along with a cover page interactive data file. The document is signed by Brian C. Evanko, the Executive Vice President and Chief Financial Officer of The Cigna Group, dated November 2, 2023.
